

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	Tralokinumab
Brand Name	Adtralza®
Dosage Form(s)	150 mg pre-filled syringe
Manufacturer	LEO Pharma Inc.
Submission Type	New Submission
Use Reviewed	Tralokinumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Tralokinumab can be used with or without topical corticosteroids.
Common Drug Review (CDR)	Yes, the CDR recommended: Do Not Reimburse . Visit the CDR website for more details: www.cadth.ca/node/88649 .
Provincial Review	Tralokinumab was reviewed internally and was not reviewed by the Drug Benefit Council (DBC) because the CDR recommended not to list for the treatment of moderate-to-severe atopic dermatitis in adult patients.
Drug Coverage Decision	Non-Benefit
Date	December 13, 2022
Reason(s)	<p>Drug coverage decision is consistent with the CDEC recommendation:</p> <ul style="list-style-type: none"> • Tralokinumab was only modestly effective in reducing atopic dermatitis symptoms and improving quality of life compared to placebo. • There was no data directly comparing tralokinumab against other systemic agents.

	<ul style="list-style-type: none"> • There is a need for more treatment options for patients whose atopic dermatitis is not controlled despite the use of existing treatments; however, the CDEC concluded the evidence reviewed did not show that tralokinumab would meet this need.
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.